Ruiz Maria Paula, Dziadek Olivia Lisa, Algren Stacey Denise
Department of Obstetrics and Gynecology, University of Missouri-Kansas City, Kansas City, MO.
Int J Gynecol Cancer. 2016 Sep;26(7):1290-2. doi: 10.1097/IGC.0000000000000759.
The aim of this study was to evaluate disease progression and overall survival in patients diagnosed with neuroendocrine carcinoma of the cervix treated with chemotherapy and radiation without surgical intervention; we hypothesize similar overall survival to the surgical intervened cases.
This study used a retrospective analysis of patients with neuroendocrine carcinoma of the cervix who were not surgically managed. Review was performed from 1990 to 2014. The data collected included demographics, stage of disease, and outcomes after each treatment. Specific chemotherapy regimen given and radiation dosage were reviewed. Overall survival and recurrence rates were calculated.
A total of 16 patients met inclusion criteria. Six patients were diagnosed with stage I; these patients had 83.3% 2-year overall survival, 83.3% 5-year overall survival, and a recurrence rate of 16.6%. Three patients were diagnosed with stage II; these patients had 66.6% 2-year overall survival, 0% 5-year overall survival, and a recurrence rate of 100%. Seven patients were diagnosed with stage IV; these patients had 14.3% 2-year overall survival and 0% 5-year overall survival and never underwent remission.
Our findings noted a comparable overall survival with lower rates of recurrence in patients with early-stage disease using chemotherapy and radiation therapy alone as primary means of treatment. Nonsurgical management of neuroendocrine carcinoma of the cervix may be of benefit in early-stage disease.
本研究旨在评估接受化疗和放疗而非手术干预的宫颈神经内分泌癌患者的疾病进展和总生存期；我们假设其总生存期与接受手术干预的病例相似。
本研究对未接受手术治疗的宫颈神经内分泌癌患者进行回顾性分析。回顾时间为1990年至2014年。收集的数据包括人口统计学资料、疾病分期以及每次治疗后的结果。对所给予的具体化疗方案和放疗剂量进行了审查。计算总生存期和复发率。
共有16例患者符合纳入标准。6例患者被诊断为I期；这些患者的2年总生存率为83.3%，5年总生存率为83.3%，复发率为16.6%。3例患者被诊断为II期；这些患者的2年总生存率为66.6%，5年总生存率为0%，复发率为100%。7例患者被诊断为IV期；这些患者的2年总生存率为14.3%，5年总生存率为0%，且从未缓解。
我们的研究结果表明，对于早期疾病患者，仅使用化疗和放疗作为主要治疗手段时，其总生存期相当，复发率较低。宫颈神经内分泌癌的非手术治疗可能对早期疾病有益。
